Pharmacological interventions enhance virus-free generation of TRAC-replaced CAR T cells

Chimeric antigen receptor (CAR) redirected T cells are potent therapeutic options against hematological malignancies. The current dominant manufacturing approach for CAR T cells depends on retroviral transduction. With the advent of gene editing, insertion of a CD19-CAR into the T cell receptor (TCR...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Jonas Kath, Weijie Du, Alina Pruene, Tobias Braun, Bernice Thommandru, Rolf Turk, Morgan L. Sturgeon, Gavin L. Kurgan, Leila Amini, Maik Stein, Tatiana Zittel, Stefania Martini, Lennard Ostendorf, Andreas Wilhelm, Levent Akyüz, Armin Rehm, Uta E. Höpken, Axel Pruß, Annette Künkele, Ashley M. Jacobi, Hans-Dieter Volk, Michael Schmueck-Henneresse, Renata Stripecke, Petra Reinke, Dimitrios L. Wagner
Format: Artigo
Jezik:Inglês
Izdano: Elsevier 2022-06-01
Serija:Molecular Therapy: Methods & Clinical Development
Teme:
gene editing
CRISPR-Cas9
chimeric antigen receptor
non-viral cell manufacturing
CAR T cells
TRAC
Online pristup:http://www.sciencedirect.com/science/article/pii/S2329050122000511
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items